Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vascular endothelial growth factor C
- Development stage
- Unknown
- Lead developer
- Herantis Pharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal, Gene Therapy (plasmid Dna), Local Injection
01
Overview
Vascular endothelial growth factor C (VEGF-C) is a secreted protein growth factor in the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, encoded by the VEGFC gene. VEGF-C promotes lymphangiogenesis (growth of lymphatic vessels) by binding and activating its primary receptor, VEGFR-3 (FLT4), on lymphatic endothelial cells, stimulating their survival, proliferation, and migration. It also can bind and activate VEGFR-2, affecting blood vessel permeability and angiogenesis. VEGF-C is essential for lymphatic system development and maintenance in mammals. Therapeutically, VEGF-C is under development and investigation, notably as Lymfactin for lymphedema treatment, and is being explored in gene therapy for augmenting lymphangiogenesis in lymphatic disorders. Overproduction is linked to tumor lymphangiogenesis and metastasis; hence, it is also a relevant oncology research target[1][2][5][7].
- Brand names
- Lymfactin
- Other names
- Flt4 ligandFlt-4 ligandFlt 4 ligandFlt4-LFlt-4-LFlt 4-Lvascular endothelial growth factor-related proteinVEGFCVRP
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on vascular endothelial growth factor C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vascular endothelial growth factor C.